Beyond Air, Inc. (NASDAQ:XAIR) Sees Large Decrease in Short Interest

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 1,180,000 shares, a drop of 24.4% from the November 30th total of 1,560,000 shares. Based on an average daily volume of 751,200 shares, the days-to-cover ratio is presently 1.6 days.

Beyond Air Trading Down 2.0 %

Shares of XAIR stock opened at $0.44 on Friday. The company has a market capitalization of $31.76 million, a price-to-earnings ratio of -0.31 and a beta of -0.23. The company has a current ratio of 5.76, a quick ratio of 5.38 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.52. Beyond Air has a twelve month low of $0.30 and a twelve month high of $2.20.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings data on Monday, November 11th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.19 million. During the same quarter in the previous year, the business posted ($0.51) earnings per share. Research analysts forecast that Beyond Air will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Beyond Air stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Beyond Air, Inc. (NASDAQ:XAIR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 87,568 shares of the company’s stock, valued at approximately $47,000. Point72 Asia Singapore Pte. Ltd. owned 0.19% of Beyond Air at the end of the most recent quarter. 31.50% of the stock is currently owned by institutional investors.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.